SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Abbott Laboratories (ABT) trades at a trailing P/E of 27.6, forward P/E of 18.0. Trailing earnings yield is 3.63%, forward earnings yield 5.55%. PEG 0.35 (Peter Lynch undervalued ≤1.0). Graham Number is $50.38.
Criteria proven by this page:
- VALUE (58/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 18.0 (down from trailing 27.6) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.35 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 3.63% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 5.55% as earnings recover.
- Analyst consensus target $137.67 (+36.2% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 80/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
58/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ABT
Valuation Multiples
P/E (TTM)27.6
Forward P/E18.0
PEG Ratio0.35
Forward PEG0.35
P/B Ratio3.45
P/S Ratio4.03
EV/EBITDA15.9
Per Share Data
EPS (TTM)$3.73
Forward EPS (Est.)$5.61
Book Value / Share$30.21
Revenue / Share$25.37
FCF / Share$4.23
Yields & Fair Value
Earnings Yield3.63%
Forward Earnings Yield5.55%
Dividend Yield2.33%
Graham Number$50.38
SharesGrow IV$191.61 (+89.6%)
Analyst Target$137.67 (+36.2%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
40.4 |
-0.59 |
2.75 |
2.71 |
2.72% |
| 2017 |
208.6 |
-2.91 |
3.22 |
3.63 |
1.86% |
| 2018 |
53.6 |
0.13 |
4.16 |
4.15 |
1.55% |
| 2019 |
41.7 |
0.78 |
4.94 |
4.81 |
1.48% |
| 2020 |
43.2 |
1.99 |
5.92 |
5.61 |
1.32% |
| 2021 |
35.3 |
0.61 |
6.98 |
5.80 |
1.28% |
| 2022 |
27.8 |
-36.74 |
5.25 |
4.41 |
1.72% |
| 2023 |
33.4 |
-2.05 |
4.94 |
4.76 |
1.86% |
| 2024 |
14.6 |
0.11 |
4.11 |
4.67 |
1.96% |
| 2025 |
33.6 |
-0.65 |
4.20 |
4.94 |
1.88% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.94 |
$20.85B |
$1.4B |
6.7% |
| 2017 |
$0.27 |
$27.39B |
$477M |
1.7% |
| 2018 |
$1.34 |
$30.58B |
$2.37B |
7.7% |
| 2019 |
$2.06 |
$31.9B |
$3.69B |
11.6% |
| 2020 |
$2.50 |
$34.61B |
$4.5B |
13% |
| 2021 |
$3.94 |
$43.08B |
$7.07B |
16.4% |
| 2022 |
$3.91 |
$43.65B |
$6.93B |
15.9% |
| 2023 |
$3.27 |
$40.11B |
$5.72B |
14.3% |
| 2024 |
$7.64 |
$41.95B |
$13.4B |
31.9% |
| 2025 |
$3.72 |
$44.33B |
$6.52B |
14.7% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$5.65 |
$5.47 – $5.76 |
$48.33B |
$47.96B – $48.51B |
6 |
| 2027 |
$6.22 |
$6.08 – $6.34 |
$52.12B |
$51.27B – $52.44B |
6 |
| 2028 |
$6.87 |
$6.69 – $7.04 |
$55.96B |
$54.71B – $57.21B |
2 |
| 2029 |
$7.59 |
$7.52 – $7.63 |
$60.3B |
$59.85B – $60.54B |
1 |
| 2030 |
$8.39 |
$8.31 – $8.43 |
$64.67B |
$64.19B – $64.93B |
1 |
